

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number  
**WO 02/075307 A1**

(51) International Patent Classification<sup>7</sup>: **G01N 33/483**

(21) International Application Number: **PCT/EP02/02868**

(22) International Filing Date: **14 March 2002 (14.03.2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
**101 12 470.8 15 March 2001 (15.03.2001) DE**

(71) Applicant and

(72) Inventor: **KELLER, Ruprecht** [DE/DE]; Geis-  
bergstrasse 90, 50939 Köln (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(74) Agent: **NOBBE, Matthias**; Viering, Jentschura & Partner,  
Centroallee 263, 46047 Oberhausen (DE).


Published:

— with international search report

[Continued on next page]

(54) Title: **METHOD FOR SAMPLE IDENTIFICATION IN A MAMMAL AS WELL AS A KIT FOR PERFORMING THIS METHOD**

### Marker A



(57) Abstract: Method as well a kit for the performance of the method for the investigation of biological samples from a mammal for at least one component, wherein the method includes the following steps: (a) Administering at least one marker substance to a mammal; (b) Waiting for a length of time which is sufficient for the at least one marker substance to reach the location of sample removal; (c) Removing a biological sample from the mammal; (d) Investigating the biological sample for the presence and/or amount of at least one marker substance or a derivative thereof; and, if the at least one marker substance or the derivative thereof is detectable in the biological sample; (e) Investigating the biological sample for an analyte.

WO 02/075307 A1



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

Method for sample identification in a mammal as well as a kit  
for performing this method

The present invention relates to a method by which a sample  
5 which was taken from an excretion, a body fluid of a mammal  
or as a tissue sample, can be identified with relation to the  
origin of the sample and, in this way, can be unequivocally  
assigned to the donor of the sample, whereby the sample can  
be investigated for an analyte. Additionally, the object of  
10 the invention is a kit for performing this method.

Diagnostic methods, methods for monitoring the course of a  
therapeutic measure, prophylactic routine investigations as  
well as forensic medical investigations on man normally  
15 include the analytical investigation of samples in the  
laboratory, such as for example blood or serum samples which  
were taken from the subject, as well as the investigation of  
excretions of the subject, such as for example urine. In view  
of the multitude of existing medical diagnosis and therapy  
20 methods for animals, a very wide variety of analytical  
methods with animal samples is today every bit as much common  
practice as well. Especially the problems having arisen in  
connection with intensive livestock farming, such as BSE  
sicknesses due to the feeding of animal meal or the admixing  
25 of illegal food additives in the form of hormones and/or  
antibiotic preparations into the mast of livestock  
necessitate an extension of regular control investigations in  
animal herds in agriculture.

30 In this context there is no question that any analytical  
investigation of a sample is only then meaningful if the  
results obtained in the investigation can also be  
unequivocally assigned to the respective donor of the sample

in order to then initiate the correct response in evaluating the experimental results.

New analysis and test methods are continuously being  
5 developed as part of scientific-technical progress. Advances in molecular biology for example allow the implementation of a series of detection methods based on DNA analysis, by which certain sicknesses in man or in animals can be diagnosed.

10 Many newer analysis and detection methods also find application in forensic medicine or, due to constantly more challenging tasks of the latter, owe their development to it, for example specific testing methods for the detection of doping substances in athletes or for the detection of drugs  
15 in vehicle drivers.

Due to the multitude of analysis methods implemented as well as their complexity, high standards are expected of the technical equipment as well as of the personnel in the  
20 laboratories who perform these investigations. Normally many samples have to be investigated simultaneously with modern analysis apparatus so that the problem of a mix-up of samples unavoidably arises, thereby leading to an incorrect assignment of the investigation results with respect to the  
25 sample donor. This problem is not new and is even exacerbated especially by the rapid development of new analysis methods and the associated growing need for their use.

Since the consequences of a mix-up or an exchange of the  
30 samples to be analyzed are different but normally undesirable, there already exist a whole series of suggestions as to how to solve this problem.

These attempts at solutions relate mainly to an improved organization of the workflow in an investigative laboratory, where the following of certain rules of behavior is intended to minimize the danger of sample mix-up. However, since many  
5 protocol steps in these analysis methods are carried out by laboratory personnel themselves, mix-ups attributable to human error cannot be completely ruled out.

Knowing this, computer-controlled monitoring of the  
10 respective protocol steps to be performed with the sample is widely used, for example by labeling the sample vessels with a computer-readable code so that the respective sample can be tracked during the entire investigation process, beginning with entry of the sample and including the processing and  
15 storage of the experimental results. This computer-monitored and computer-controlled sample analysis therefore allows a large number of parallel determinations of different samples without a significant danger of mix-ups.

20 It is however clear to one of ordinary skill in the art that even the cleverest system of monitoring the samples to be investigated in a laboratory and of assigning the test results to these samples and, with this assignment, to the sample donors, cannot completely exclude a mix-up or an  
25 exchange of the samples, since only an inadequate marking of the samples or of the test results thereof can take place.

The described problem of a mix-up or an exchange of samples is especially heightened in fields of application in which  
30 the test results can be used as incriminating evidence against the sample donor or, in the case of a sample originating from a livestock animal, against the owner of the animal. In these cases there exists a special interest of the

subject or of the owner to tamper with the test samples in order to avoid the generation of incriminating evidence.

However, it is especially in these cases that an unequivocal assignment of the test results to the sample donor are especially important, since certain legal regulations can often only be enforced in this way.

The attempts at solutions which, in view of this problem, already exist in the prior art for preventing tampering with the sample relate exclusively to the monitoring of sample removal. For example it is common practice that the submission of urine from subjects taking part in methadone therapy is supervised.

However, even the most clever monitoring and supervision of subjects during the submission of the urine sample will not completely prevent an exchange of the samples. In Germany 20,000 of the 120,000 - 140,000 drug addicts are already treated with methadone. A major increase in this number is to be expected in the future. Since methadone patients often take other narcotics as well as barbiturates and tranquilizers, a control of the substances taken by the patients is therapeutically necessary.

According to the guidelines for the implementation of methadone therapy, the urine must be checked at least once a week or, under certain circumstances, even more frequently. Normally, submission of the urine sample under observation is not possible in normal doctors' offices since commonly only a small restroom is present and normally male medical personnel are not at adequate disposal to accompany the male methadone patients. The construction of restrooms suitable for sample

submission under observation requires a high financial outlay. Just the costs for such investment in the health office of Duesseldorf came to 50 TDM.

5 Due to the commonly observed tampering of submitted urine samples, work is increasingly being done on analysis methods for detection of drugs in saliva discharge. Even if, in contrast to using blood, plasma or urine as test samples, a saliva sample can be obtained without a damaging intrusion or  
10 without intruding upon the subject's privacy, the danger of a negligent mix-up of or an intentional tampering with the samples still cannot be prevented.

The goal of the present invention is therefore to ensure an  
15 unequivocal assignment of the samples to the donor and, in this way, to overcome the problems or disadvantages common to the prior art.

According to the invention this goal is met by providing a  
20 method for the investigation of biological samples from a mammal for at least one component, wherein the method includes the following steps:

- (a) Administering at least one marker substance to a mammal;
- 25 (b) Waiting for a length of time which is sufficient for the at least one marker substance to reach the location of sample removal;
- (c) Removing a biological sample from the mammal;
- (d) Investigating the biological sample for the presence  
30 and/or amount of at least one marker substance or a derivative thereof; and, if the at least one marker substance or the derivative thereof is detectable in the biological sample;

(e) Investigating the biological sample for an analyte.

The idea of the present invention was therefore to find a possibility with which the sample to be investigated can be marked while preventing this marker from being removed from the sample by methods accessible to a layperson. The method is therefore suitable for example for monitoring methadone therapy as well as for doping checks. Advantageous marking substances are in general characterized by a series of specific characteristics. These marker substances exert no pharmacological side effects on the organism of the mammal at the concentrations which are necessary for detection of these marker substances in the blood, in the urine or other body fluids or in body excretions according to the invention.

A derivative which is specifically formed from the at least one marker substance can also just as well be used in place of the latter. By „derivatives“ are to be understood all subsequent products which arise as a result of a chemical transformation in the organism of the subject or in the removed sample, wherein however all subsequent products are excluded which are not exclusively attributable to the transformation of a specific marker in the subject organism or in the removed sample.

It is advantageous if the marker substances are soluble in a liquid, that the normal taste of the liquid such as for example juice is not changed by the addition or that, following dissolving in water, no unpleasant taste of the resulting solution is caused by the marker substances and, therefore, the subject can willingly drink the liquid containing the markers.



Advantageous marker substances are characterized in that they are absorbed quickly through the intestinal mucous membranes and are excreted from the subject in the urine. It is further advantageous if these marker substances in urine samples can  
5 be detected in as simple a manner as possible by detection methods already established in chemical investigation laboratories such as for example common methods of clinical analytical chemistry. According to the invention, it is preferable to use marker substances which are not metabolized  
10 following uptake by the subject.

Preferred marker substances are sugars or sugar derivatives such as for example arabinose, erythrulose, *myo*-inositol, *cis*-inositol, mannitol, sorbose, rhamnose, sorbitol, xylose  
15 and xylulose, which are soluble in water and which can be easily detected by enzymatic tests.

It is also advantageous to use isoprenoids, lipids, saccharides, polyols, polyethylene glycols, derivatives or  
20 mixtures of these substances as the marker substance.

Especially preferred is the use of the method according to the invention in the investigation of urine samples. For this, the marker substance or a combination of multiple  
25 marker substances is dissolved in a liquid, and the liquid is orally administered in that the subject drinks the liquid approximately 30 to 60 minutes before the urine submission. Polyethylene glycols or mixtures thereof are most preferably used as marker substances for the investigation of urine  
30 samples.

It is especially preferable to administer multiple marker substances simultaneously, wherein it is possible by the

combination of marker substances to develop a certain numerical code belonging to a respective sample. In order to increase the safety against tampering, it is preferred to administer a combination of at least 2, especially preferred of at least 3, very especially preferred of 5 marker substances simultaneously.

Using a total of  $n$  marker substances, there exist  $2^n - 1$  different combinations in a dual numeric system. Tampering with the samples by the subject is therefore impossible since the subject would have to know the chemical nature of the marker substances, the numerical code for his urine sample and the sequence of marker substances according to which the code is constructed.

The administration of the marker substance can be accomplished in different ways. By „administration“ is to be understood the introduction of one or a multitude of marker substances into the organism of the sample donor. According to the invention, the marker substance or the multitude of marker substances can be administered to the sample donor preferably parenterally or orally. It is especially preferred that the marker substance or the multitude of marker substances be taken up via the digestive tract and that, during uptake, no metabolization of the marker substances takes places.

Depending on the type of the at least one marker substance administered and the type of the sample to be removed, it is necessary prior to the removal of the sample to be investigated to wait a certain „sufficient length of time“ before sample removal. This length of time represents the time which the at least one marker substance requires to

reach the location of sample removal. In the case of sample removal from a component existing separately from the sample donor, such as for example sample removal from a body excretion, the time is to be understood as being that time which is required until the at least one marker substance is present in the separable component and this component is separated from the sample donor. The amount of time one must wait can be empirically determined, wherein however in most cases the corresponding values or methods for their determination are known in the prior art (van Rossum, J. M.: Kinetics of Drug Action. Handbuch der experimentellen Pharmakologie, Vol. 47. Springer, Berlin 1977; Forth, W.: Allgemeine und spezielle Pharmakologie und Toxikologie. Bibliographisches Institut & F. A. Brockhaus, Mannheim 1988).

Sample removal occurs in different ways depending on the type of sample to be investigated. In the case of the analysis of body excretions, part of the sample is taken up into a sample vessel and, after this time, is ready for further investigation. In the investigation of human urine or stool samples, the samples can usually be furnished by the subjects themselves in that the subject is simply given a sample vessel. For the removal of samples from body fluids or from tissue samples, a direct operation on the subject is normally necessary. Here, obtention of blood from the subject can be accomplished using a suction pipette following pricking or cutting of the skin with a disposable lancet or - in larger quantities - using an injection syringe or blood collection tube (German: Venüle) after puncture of the vein. For the investigation of liquor, the latter is obtained by lumbar, suboccipital or ventricle puncture.

By „biological sample“ is meant the components of a mammal designated for the analytical investigation. Relevant here are body excretions, body fluids or tissue samples. The components making up the sample can include components of a mammalian organism which still exist in the mammal at the time of sample removal as well as previous components of the mammal.

By „body excretions“ or „excretion“ are to be understood urine, stool, secretions from salivary, milk, tear and sweat glands.

By „body fluid“ are to be understood extracellular liquids of a mammalian organism like blood, serum and liquor.

By „mammal“ are to be understood in addition to animals of this category man as well.

Preferably, the samples removed from or excreted by a mammal are body excretions, body fluids or tissue samples.

By „tissue sample“ is to be understood an organization of identically differentiated cells obtained by a direct operation into the living mammalian organism, as well as these cells' intercellular substance. Hair samples and samples of sloughed-off parts of skin are also to be understood as falling within the meaning of this term.

Depending on the type of the sample and the at least one marker substance to be detected, the respective sample has to be prepared prior to the analysis method. The preparation steps can include centrifugation for the separation of solid, non-solubilized materials in a liquid sample such as for

example urine, solubilization or suspension of solid samples such as for example stool, concentration by ion-exchange chromatography using Centricons, by precipitation with suitable reagents such as ammonium sulfate, adjustment of the pH value required for the analysis method, homogenization of the sample such as by ultrasonication or by using vibration cell mills in order to, for example, be able to investigate components from originally intact tissues, separation of materials used in lysing the sample such as for example detergents and other preparation steps known to one of ordinary skill in the art.

A number of enzymatic, immunological, mass-spectroscopic and electrophoretic detection methods as well as combinations of these methods are available for the determination of the presence or absence of at least one marker substance in a sample. Preferably, detection is accomplished by a coupled GC/MS or HPLC/MS method or by HPLC or GC. These methods allow the very time-efficient investigation of, in particular, liquid samples or of samples which, due to their preparation were transferred into a liquid. At the same time, these detection methods allow a high degree of automatization so that a multitude of samples can be analyzed in a short time and, in as far the chromatograms and, as the case may be, mass spectroscopic fractionation patterns of reference substances already exist in the computer evaluation unit, the actual detection of the at least one marker substance is also greatly simplified.

If it is determined as a result of the evaluation of the analysis method applied that the originally administered at least one marker substance is present in the investigated sample, then this allows the unequivocal assignment of this

sample to the subject. If this requirement is fulfilled, i.e. that the sample originates from the subject being investigated, the actual investigation of this sample or, alternatively, of a second sample for an analyte takes place.

5

By „analyte“ is to be understood at least one chemical substance, wherein the knowledge as to the presence or, as the case may be, also of its concentration in the sample, allows a conclusion as to a past, expected or present condition of the sample donor. As an example, a conclusion as to an incorrectly functioning - because incomplete - resorption of glucose from the urine by the kidney tubules (glucosuria) in a subject is made possible on the basis of knowledge of the concentration of an analyte such as for example the glucose concentration in the urine of a urine sample, which was normally enzymatically determined by means of glucose oxidase (GOD) or hexokinase. Analytes can further be intoxicants, medicines, metabolites of the previously named substances, the detection of which in the sample yields information as to the behavior or a treatment of the subject.

20

In addition to the use of the method according to the invention in human medicine, there also exist a multitude of further applications in the veterinary medical field and in agriculture. The method can advantageously be used in the monitoring of adherence to regulations for the use of feed additives in agricultural livestock mast farming.

25

If for example samples obtained from mast pigs are to be investigated for the presence of growth hormones or antibiotics or their metabolites, the use of the method according to the invention can avoid the problem of a

30

tampering with the samples to be investigated by the owner of the herd of mast pigs.

Here, especially those marker substances are advantageous  
5 which remain in the animal over a long length of time - in the ideal case over the entire duration of masting - yet which are still continuously present in a detectable amount, for example in a body excretion. For this reason, those marker substances are advantageous which can be administered  
10 to the animal as a time-release agent, by virtue of which for example a time-delayed yet continuous resorption through the intestinal mucous membranes takes place and therefore the at least one marker substance is detectable over a longer length of time, for example in a body excretion like animal feces.  
15 Especially suitable samples are samples with which both the investigation for the at least one marker substance as well as the detection or the concentration determination of at least one analyte takes place.

20 Another object of the present invention is a kit for performing the described method for sample identification in a mammal, wherein the kit according to the invention includes a marker substance in a container such as a tablet vessel as well as, as the case may be, means for administering the at  
25 least one marker substance to the mammal.

It is especially advantageous if this kit also contains at least one reference substance for the detection of the marker substance or the multitude of marker substances.

30

A kit according to the invention preferably contains, for the oral administration of the marker substances, these marker substances in the form of individual water-soluble

effervescent tablets. Alternatively, these effervescent tablets can also already contain the marker substances as mixtures of multiple marker substances. The respective substance code can then be taken from the label of the tablet vessel.

The kit can comprise effervescent tablets with varying concentrations of marker substances corresponding to the circle of people to whom the marker is to be administered, so that these marker substances can be applied for example to children as well as adults without reaching a concentration of marker substances in the subject at which pharmacological side effects can arise.

It is especially advantageous if the tablet vessels contained in the kit are provided with a computer-readable code. Kits intended for the marking of urine samples of methadone patients preferably contain tablets, capsules, or similar application forms in which both the amount of methadone to be administered as well as the mixture of marker substances are available together.

Further advantageous embodiments of the kit according to the invention include multiple reference substances by means of which the marker substances can be easily identified in the chromatographic analysis of the sample, such as for example in the investigation of the urine sample.

In, for example, the investigation of the urine sample of a patient treated with methadone, an ampoule tube can also be present in the kit according to the invention, which ampoule tube contains a mixture of marker substances solubilized in a suitable carrier means according to the chosen



chromatographic method, wherein this mixture corresponds exactly to the mixture present in the corresponding methadone tablets.

- 5 By a subsequent run on the same GC column, it can be determined very quickly and with certainty due to the chromatography peaks of the marker substances in a GC analysis whether the investigated urine sample originates from the patient being treated with methadone.

10

#### Example 1

For the further exemplary explanation of the method according to the invention, an embodiment for performing the marking of  
15 a sample to be investigated is provided below.

The embodiment relates to the marking of a urine sample to be investigated and its subsequent investigation. The subject receives 100-300 ml of liquid to drink, in which 1 g  
20 polyethylene glycol 600 is solubilized as a marker substance. Fruit juices, water, and other liquids palatable to humans can be used as liquids to drink.

In place of polyethylene glycol 600, monodisperse fractions  
25 or mixtures of monodisperse fractions can also be used. Here, the laboratory establishes a substance code. Such a code is given in the following as five monodisperse polyethylene glycol fractions. Here, „0“ stands for not present and „1“ stands for present.

30

Substances	Substances				
	A	B	C	D	E
Code					
1	0	0	0	1	1
2	0	0	1	0	1
3	0	0	1	1	0
4	0	0	1	1	1
5	0	1	0	0	1
6	0	1	0	1	0
7	0	1	0	1	1
8	0	1	1	0	0
9	0	1	1	0	1
10	0	1	1	1	0
11	1	0	0	0	1
12	1	0	0	1	0
13	1	0	0	1	1
14	1	0	1	0	0
15	1	0	1	0	1
16	1	0	1	1	0
17	1	1	0	0	0
18	1	1	0	0	1
19	1	1	0	1	0
20	1	1	1	0	0

The substances A, B, C, D and E correspond to polyethylene glycol fractions with molecular weights:

A	530
B	574
C	618
D	662
E	706

After ingestion the subject was requested to wait at least 30 minutes and at the most 4 hours before urinating. The subject  
5 was allowed to consume further liquids or solid food during this waiting phase. The subject did not have to be supervised during the waiting time. The submission of urine by the subject took place without supervision.

10 The sample vessel was identified with a barcode label coding a job number also contained on the computer-readable accompanying tag. On the accompanying tag were noted the name of the subject, the desired investigation as well as the combination of marker substances or the substance code. The  
15 sender is saved by the job number in the master data of the lab computer. The samples were transported to the laboratory with the accompanying tag. The accompanying tag was entered into the computer with a card reader. The job was recorded in this way. Here, the substance combination or the substance  
20 code was also entered into the computer.

For the analysis for polyethylene glycol, the urine was centrifuged, 100 µl of the supernatant was given on Nucleosil C 100 - (C18), 3 µm (4.6 x 125 mm) at a flow rate of 0.5  
25 ml/min (methanol/water 5/95) and was investigated for polyethylene glycol by detection with an RI detector. The chromatography peaks were identified as polyethylene glycols

by the retention times based on the reference chromatographies.

In this way, each investigated urine sample could be unequivocally assigned to the respective subject via the substance code of the different polyethylene glycol fractions used. The subject was subsequently investigated for the analyte, i.e. an intoxicant to be detected like heroin or its derivatives.

Sugars for marking body fluids can be used in the same manner as described for polyethylene glycol fractions. These are determined from urine or other body fluids via enzymatic detection reactions. The analytical detection methods required for this are known in the prior art (Methods of Enzymic Analysis, ed. Bergmeyer, H.U. VCH Verlagsgesellschaft mbH, Weinheim 1986).

#### Example 2

For pre-analytical patient preparation, patients of drug ambulances were given 1 ml of polyethylene glycole 400 ("Marker A"), 600 ("Marker B") or a mixture of 400 and 600 ("Marker C") in 100 ml fruit juice. Patients were supervised while drinking and asked to wait for at least 30 min prior to urine delivery. After that time patients were allowed to urinate without supervision. The urine tube was then labeled and directly transported to the site of analysis.

Before analysis, the sample were prepared as follows: 10 ml urine was centrifuged at 10500 x g for 10 min.

For polyethylene glycole analysis, the chromatograph was operated isocratically at ambient temperatures in the column-switching mode. Because RI detection limits to isocratic

mobile phases, eluent of cleanup and analytical pump were identical, consisting of 44% methanol and 56% water. 100 µl supernatant of the centrifuged urine were injected automatically onto a (60 x 4.6 mm) precolumn filled with Nucleosil 100 C18, 5 µm. With the eluent delivered by the clean-up pump at a flow of 0.4 ml / min and a pressure of 36 bar, matrix impurities were discharged to the waste, while the PEG fractions were retarded on the stationary phase. After 120 sec the precolumn was switched by the six-port valve to the eluent stream of the analytical pump, and the analytes were backflushed for separation with a flow rate of 0.5 ml/min and a pressure of 96 bar onto the analytical column, Nucleosil 100 C8 5 µm. Analysis time took 18 min. Phenomenological characterization of the urinary chromatographic elution pattern was achieved by RI-detection, set at 40 °C. According to the observed pattern, markers were then diagnosed as "Marker A", "Marker B" or "Marker C" as shown in the attached Figures 1-3.

The following materials and equipments have been used in this example: Polyethylene glycole, PH Eur quality, of the average molecular weight 400 or 600 from Merck, Darmstadt, Germany; HPLC-grade methanol and acetonitrile from Baker; water deionized and purified by Millipore systems Elix3 and MilliQ Gradient A10, Inertsil C8-3 5µm, (250x4.6), and Nucleosil 100 C18 5 µm (50x4.6 mm) HPLC columns from Schambeck SFD GmbH, Bad Honnef, Germany. HPLC-Equipment: sample injector S 5200 fitted with a 100 µl injection loop, precolumn clean-up pump S 2100, degaser integrated, six-port motor switching valve ProLAB, column oven SFD 125-600, refraction index detector of deflection type, inline filter element PAT<sup>TM</sup>, for PEEK 3µm inline filters was obtained from Schambeck SFD GmbH, Bad Honnef, Germany. Analytical pump M480, degassing module

degasys DG1310 and data acquisition system Chromeleon 6.11 under Windows NT 4.0 were purchased from Gynkotec.

Claims

1. Method for the investigation of biological samples from a mammal for at least one component, wherein the method  
5 includes the following steps:
- (a) Administering at least one marker substance to a mammal;
  - (b) Waiting for a length of time which is sufficient for  
10 the at least one marker substance to reach the location of sample removal;
  - (c) Removing a biological sample from the mammal;
  - (d) Investigating the biological sample for the presence and/or amount of at least one marker substance or a  
15 or the derivative thereof is detectable in the biological sample;
  - (e) Investigating the biological sample for an analyte.
2. Method according to claim 1, wherein the at least one  
20 marker substance is chosen from isoprenoids, lipids, saccharides, polyols, polyethylene glycols or derivatives thereof.
3. Method according to claim 2, wherein arabinose,  
25 erythrulose, *myo*-inositol, *cis*-inositol, mannitol, sorbose, rhamnose, sorbitol, xylose and xylulose are chosen as saccharides.
4. Method according to any of the previous claims, wherein at  
30 least one polyethylene glycol is used as a marker substance.

5. Method according to claim 1, wherein the at least one marker substance is supplied to the recipient parenterally or orally.

5 6. Method according to any of the previous claims, wherein the removal of a biological sample from the mammal is accomplished by collection of urine in a collection vessel or by removal of blood by means of an injection syringe from an artery or by means of a blood collection tube following  
10 puncture of the vein.

7. Method according to any of the previous claims, wherein the biological sample includes body excretions, body fluids or tissue.

15 8. Method according to claim 7, wherein the body excretion is urine.

9. Method according to any of the previous claims, wherein  
20 the marker substance or the multitude of marker substances is detected by means of GC, GC/MS, HPLC or HPLC/MS.

10. Method according to claim 1, wherein urine samples from patients treated with methadone are investigated for  
25 intoxicants and the method includes the following steps:

- (a) Administering a combination of  $2^n-1$  polyethylene glycols of different molecular weight orally to a patient treated with methadone, wherein  $n$  is a whole number and greater than zero, preferably at least 2, especially  
30 preferred at least 3, very especially preferred 5;
- (b) Waiting for a length of time of at least 30 minutes up to at most 4 hours;



(c) Removing a urine sample from the excreted urine of the patient;

(d) Investigating of the urine sample for the presence of the administered polyethylene glycols and; as the case may  
5 be,

(e) Investigating of the urine sample for intoxicants.

11. Kit for performing the method according to any of the previous claims, wherein the kit includes, in a container, at  
10 least one marker substance, preferably at least 2, especially preferred at least 3, and very especially preferred 5.

12. Kit according to claim 11, wherein the kit contains a combination of  $2^n-1$  polyethylene glycols of different  
15 molecular weight in one or more containers.


13. Kit according to claim 11 or 12, wherein the kit additionally includes means for administering the at least one marker substance.

20 14. Kit according to claim 13, wherein the kit additionally includes means for detection of the at least one marker substance in the sample removed from a mammal.

25 15. Kit according to claim 13, wherein the kit additionally contains reference substances for the detection of the at least one marker substance.


Figur 1/3

## Marker A




Figur 2/3

## Marker B



Figur 3/3

## Marker C



## INTERNATIONAL SEARCH REPORT

ational Application No  
PCT/EP 02/02868

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 G01N33/483

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

PAJ, EPO-Internal, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 179 027 A (FISHER MURRAY M) 12 January 1993 (1993-01-12) column 2, line 49 -column 3, line 11	11,13-15
X	WO 98 14275 A (INTRONN LLC ;MITCHELL LLOYD G (US)) 9 April 1998 (1998-04-09) page 3, line 30 -page 5, line 29	11,13-15
X	PATENT ABSTRACTS OF JAPAN vol. 2000, no. 04, 31 August 2000 (2000-08-31) & JP 2000 028614 A (NITTO DENKO CORP), 28 January 2000 (2000-01-28) abstract	11,13-15
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

12 August 2002

Date of mailing of the international search report

21/08/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Thomte, M

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 02/02868

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 531 682 A (MAZER TERRENCE B ET AL) 2 July 1996 (1996-07-02) column 16, line 35 -column 17, line 53; figures 14,10 -----	11,13-15
A	US 5 093 265 A (SHUG AUSTIN L ET AL) 3 March 1992 (1992-03-03) column 10, line 43 -column 10, line 55 -----	12
A	WO 00 74781 A (CLEMENT ROBERT MARC ;KIERNAN MICHAEL NOEL (GB); SLS BIOPHILE LTD ( ) 14 December 2000 (2000-12-14) figures 4,5 -----	11-15

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 02/02868

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-10  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy  
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International App.  
PCT/EP 02/02868

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5179027	A	12-01-1993	NONE	
WO 9814275	A	09-04-1998	AU 735272 B2 AU 4738697 A EP 0938381 A1 JP 2001510557 T WO 9814275 A1	05-07-2001 24-04-1998 01-09-1999 31-07-2001 09-04-1998
JP 2000028614	A	28-01-2000	EP 1020726 A1 WO 0002049 A1	19-07-2000 13-01-2000
US 5531682	A	02-07-1996	AT 216898 T AU 711357 B2 AU 3080897 A CA 2210316 A1 DE 69620997 D1 EP 0802806 A1 JP 2001519682 T NZ 327094 A WO 9621479 A1 US 5755689 A	15-05-2002 14-10-1999 28-07-1997 18-07-1996 06-06-2002 29-10-1997 23-10-2001 29-11-1999 18-07-1996 26-05-1998
US 5093265	A	03-03-1992	AU 624596 B2 AU 2946489 A EP 0390870 A1 WO 8905979 A1	18-06-1992 19-07-1989 10-10-1990 29-06-1989
WO 0074781	A	14-12-2000	AU 5094500 A BR 0012108 A CN 1353620 T EP 1183071 A1 WO 0074781 A1 NO 20015808 A	28-12-2000 02-07-2002 12-06-2002 06-03-2002 14-12-2000 21-01-2002